Gavin P. Reynolds
Department of Psychiatry
Queen's University Belfast
Belfast BT9 7BL
UK
Name/email consistency: high
- Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms. Reynolds, G.P., Kirk, S.L. Pharmacol. Ther. (2010)
- The impact of pharmacogenetics on the development and use of antipsychotic drugs. Reynolds, G.P. Drug Discov. Today (2007)
- Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. Reynolds, G.P., Arranz, B., Templeman, L.A., Fertuzinhos, S., San, L. Am. J. Psychiatry (2006)
- The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics. Reynolds, G.P., Hill, M.J., Kirk, S.L. J. Psychopharmacol. (Oxford) (2006)
- Pharmacogenetics of schizophrenia. Reynolds, G.P., Templeman, L.A., Godlewska, B.R. Expert. Opin. Pharmacother (2006)
- Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. Reynolds, G.P., Yao, Z., Zhang, X., Sun, J., Zhang, Z. Eur. Neuropsychopharmacol (2005)
- The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Reynolds, G.P., Templeman, L.A., Zhang, Z.J. Prog. Neuropsychopharmacol. Biol. Psychiatry (2005)
- Receptor mechanisms in the treatment of schizophrenia. Reynolds, G.P. J. Psychopharmacol. (Oxford) (2004)